In the mouse tumor model, administering tumor-opsonizing antibodies with inhibition of this phagocytosis checkpoint promoted therapeutic efficacy (14, 15), and SIRPα-deficient macrophages showed activation of cytotoxic T cells by conducting immunogenic antigen presentation (16). Here, SIRPA is linked to neoplasm.